- Home
- CLNN
CLNN
Clene Inc.
as 03-31-2025 4:00pm EST
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 35.9M | IPO Year: | N/A |
| Target Price: | $55.25 | AVG Volume (30 days): | 49.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.95 - $9.20 | Next Earning Date: | 03-24-2025 |
| Revenue: | $342,000 | Revenue Growth: | -47.71% |
| Revenue Growth (this year): | -15.5% | Revenue Growth (next year): | 16370.78% |
Latest Clene Inc. News
CLNN Breaking Stock News: Dive into CLNN Ticker-Specific Updates for Smart Investing
NewMediaWire
7 days ago
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025
GlobeNewswire
8 days ago
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
Simply Wall St.
12 days ago
Bullish Clene Insiders Loaded Up On US$583.4k Of Stock
ACCESS Newswire
13 days ago
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
GlobeNewswire
20 days ago
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
GlobeNewswire
a month ago
Clene to Present at the 37TH Annual Roth Conference
ACCESS Newswire
a month ago
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11
GlobeNewswire
a month ago
Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction
Compare CLNN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLNN Clene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.